Ai3Bio, a biotech built from the merger of two earlier companies, is pursuing a different route to an 'immune reset' for autoimmune disease. According to BioPharma Dive, its therapies are designed to eliminate a specific group of T helper cells, rather than deplete malfunctioning B cells as many other emerging autoimmune drugs do.
The distinction is central to the company's positioning. While B-cell depletion has become a common strategy in autoimmune drug development, Ai3Bio's approach focuses on a particular T helper cell population, which the company believes offers an alternative way to reset the immune system.
Because the report is based on a single company announcement, there are no independent comparisons or clinical data to weigh. The approach is still early-stage, and the source does not provide regulatory timelines or efficacy results.